Results 141 to 150 of about 17,078 (163)

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

Journal of Urology, 2010
, Christopher R Chapple, VÍCTOR W Nitti
exaly  

Overactive Bladder in Children. Part 1: Pathophysiology

Journal of Urology, 2007
Israel Franco
exaly  

How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study

BJU International, 2001
Linda Cardozo, J Thuroff, A J Wein
exaly  

Urinary Nerve Growth Factor Level Could be a Potential Biomarker for Diagnosis of Overactive Bladder

Journal of Urology, 2008
Hsin-Tzu Liu, Hann-Chorng Kuo
exaly  

Mirabegron in overactive bladder patients: efficacy review and update on drug safety

Therapeutic Advances in Drug Safety, 2016
Katherine Warren, Helena Burden, Paul Abrams   +2 more
exaly  

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

Journal of Urology, 2013
VÍCTOR W Nitti, , Sender Herschorn
exaly  

A case controlled study examining the bladder microbiome in women with Overactive Bladder (OAB) and healthy controls

European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017
Aswini Balachandran, Claire M Peppiatt-Wildman, Scott A Wildman   +2 more
exaly  

Overactive Bladder and Mental Health Symptoms in Recently Deployed Female Veterans

Journal of Urology, 2014
Catherine S Bradley, Íngrid E Nygaard, Stephen L Hillis   +2 more
exaly  

Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy

Journal of Urology, 2016
Scott Macdiarmid, Jack Barkin, Aino Fianu-Jonasson   +2 more
exaly  

Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome

Journal of Urology, 2007
VÍCTOR W Nitti, Marina Brodsky, Tamara Bavendam   +2 more
exaly